Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Lupin, Astellas Settle Mirabegron Patent Dispute for USD 90 Million

    Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).

    Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.

  • Oxygen-Boosted Microneedle Patch Shows Promise for More Effective Psoriasis Treatment

    Researchers have developed an innovative oxygen-boosted microneedle patch that significantly improves drug delivery and photodynamic therapy (PDT) for psoriasis, a chronic inflammatory skin disease that affects millions worldwide.

    The study, published in Acta Pharmaceutica Sinica B, describes a dual-section microneedle (MN) patch designed to overcome two major challenges in psoriasis treatment: poor drug penetration through thickened skin and reduced efficacy of PDT caused by low oxygen levels in inflamed lesions.

  • Wearable Bioelectronics Pave the Way for Future Personal Health Monitoring

    Advances in soft and sustainable wearable bioelectronics are set to transform personal health monitoring and digital healthcare, according to a new Perspective article published in BIO Integration. Researchers highlight how skin-like wearable systems can continuously track health signals during daily life, moving care beyond occasional hospital visits.

  • Path Opens for CGHS Pharmacists to Become Gazetted Officers
    In a major and long-awaited development, the Central Government has notified the Recruitment Rules for the posts of Depot Manager (DM) and Assistant Depot Manager (ADM) under the Central Government Health Scheme (CGHS).
  • New research strengthens the potential of mycoprotein as an alternative to meat
    Researcher Ricky Wang delved into these issues and recently presented his findings in his doctoral thesis In vitro Gastrointestinal Fate of Edible Filamentous Fungi : Protein and Mineral Digestibility for Food Applications.
  • AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®)
    The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with NSV.
  • Alembic Pharma Wins USFDA Nod for Parkinson Combination Therapy Tablets
    Alembic Pharmaceuticals Limited has strengthened its US generics portfolio with the final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Carbidopa, Levodopa and Entacapone Tablets.
  • Zydus Desidustat Secures USFDA Orphan Drug Status for Sickle Cell Therapy

    Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.

  • Blocking pain at the source : Hormone therapy rewires nerve signals in aging spines

    Low back pain (LBP) is one of the most common health problems worldwide, affecting people of all ages and placing a heavy burden on healthcare systems. Many patients experience persistent discomfort that interferes with work, sleep, and daily activities. Yet in most cases, doctors cannot identify a clear structural cause, making long-term treatment difficult.

  • Emcure Pharmaceuticals Posts Strong Q3 FY26 Performance; profit Surges 48%

    Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.

Subscribe to Pharma News